Healthcare company Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) on Monday reported an increase in revenues for the third quarter of 2023. The company also
Vertex Pharmaceuticals Incorporated
-(VRTX)
XNAS:VRTX
Vertex Pharmaceuticals (VRTX) Earnings: 2Q23 Key Numbers
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) reported product revenue of $2.49 billion for the second quarter of 2023, which was up 14% year-over-year. Net
VRTX Earnings: A snapshot of Vertex Pharmaceuticals’ Q1 2023 results
Healthcare firm Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) on Monday reported a decline in adjusted earnings for the first quarter, despite an increase in
Vertex Pharmaceuticals (VRTX) Earnings: 4Q22 Key Numbers
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) reported total revenues of $2.3 billion for the fourth quarter of 2022. This compares to $2 billion in
Vertex Pharmaceuticals Incorporated (VRTX) Q4 2022 Earnings Call Transcript
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) Q4 2022 earnings call dated Feb. 07, 2023 Corporate Participants: Susie Lisa -- Senior Vice President, Investor Relations Reshma
Vertex Pharmaceuticals Incorporated (VRTX) Q3 2022 Earnings Call Transcript
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) Q3 2022 earnings call dated Oct. 27, 2022 Corporate Participants: Susie Lisa -- Senior Vice President, Investor Relations Reshma
Vertex Pharmaceuticals Incorporated (VRTX) Q4 2021 Earnings Call Transcript
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) Q4 2021 earnings call dated Jan. 26, 2022 Corporate Participants: Michael Partridge -- Senior Vice President of Investor Relations
Vertex Pharma (VRTX) expands cystic fibrosis pipeline; raises FY21 outlook
Biotechnology company Vertex Pharmaceuticals (NASDAQ: VRTX) has reported higher earnings and revenues for the third quarter of 2021. The bottom line also
Vertex Pharmaceuticals Inc (VRTX) Q1 2021 Earnings Call Transcript
Vertex Pharmaceuticals Inc (NASDAQ: VRTX) Q1 2021 earnings call dated Apr. 29, 2021 Corporate Participants: Michael Partridge -- Senior Vice President of Investor Relations
Vertex Pharmaceuticals reports 14% growth in Q1 revenue: Infographic
Vertex Pharmaceuticals (NASDAQ: VRTX) reported first-quarter 2021 financial results after the regular market hours on Thursday. The pharmaceutical firm reported Q1 revenue
It’s worth keeping an eye on Vertex Pharma (VRTX) stock. Here’s why
After dominating the cystic fibrosis market for quite some time, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) is currently expanding its clinical programs to
Vertex Pharmaceuticals Inc (VRTX) Q4 2020 Earnings Call Transcript
Vertex Pharmaceuticals Inc (NASDAQ: VRTX) Q4 2020 earnings call dated Feb. 01, 2021 Corporate Participants: Michael Partridge -- Senior Vice President of Investor Relations
Infographic: Vertex Pharmaceuticals (VRTX) 4Q20 Earnings Results
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) reported fourth quarter 2020 earnings results today. Total revenues increased 15% year-over-year to $1.62 billion. GAAP net
Vertex Pharmaceuticals Inc. (VRTX) Q2 2020 Earnings Call Transcript
Vertex Pharmaceuticals Inc (NASDAQ: VRTX) Q2 2020 earnings call dated July 30, 2020 Corporate Participants: Michael Partridge -- Senior Vice President, Investor Relations Reshma
Vertex Pharmaceuticals Inc (NASDAQ: VRTX) Q1 2020 Earnings Call Transcript
Vertex Pharmaceuticals Inc (VRTX) Q1 2020 earnings call dated Apr. 29, 2020 Corporate Participants: Michael Partridge -- Senior Vice President of Investor Relations Reshma
Vertex Pharmaceuticals (VRTX) reports Q1 2020 earnings results
Vertex Pharmaceuticals (Nasdaq: VRTX) today reported first quarter financial results for the period ended March 31, 2020. On GAAP basis, first quarter
What to expect from Vertex Pharmaceuticals (VRTX) Q1 2020 earnings?
Biotechnology is the one industry that has been showing signs of improvement in the COVID-19 affected market. This week a bunch of
Vertex Pharmaceuticals (VRTX) stock soars to record high on bullish outlook
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) continues to be in the luxury of escaping from the COVID-19 pandemic crisis. The stock reflected the
Vertex Pharmaceuticals (VRTX): Q3 2019 Earnings Snapshot
-- Vertex Pharmaceuticals (NASDAQ: VRTX) reported third-quarter 2019 earnings of $1.23 per share, vs. $1.15 per share expected -- Total revenue grew
Vertex Pharmaceuticals Q2 profit jumps 29%, beats estimates
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) reported a 29% jump in earnings for the second quarter of 2019 helped by strong growth in
Top biotech stocks to be considered for investment this year
When the massive selloff battered Wall Street in the final months of 2018, biotechnology stocks were no exception. And, most of them